-
Eur Heart J: BBs and ACEI/ARBs are used to prevent left ventricular dysfunction caused by anthracyclines or trastuzumab in breast cancer patients
Time of Update: 2022-01-08
The researchers performed a secondary analysis of the effects of BBs or ACEI/ARBs on LVEF in patients receiving trastuzumab and anthracyclines .
It can be seen that during trastuzumab and anthracycline-containing drugs, compared with placebo, taking BB and ACEI/ARB treatments are both associated with maintaining LVEF, indicating that both are beneficial to the heart .
-
Ther Adv Med Oncol: Bendamustine (bendamustine) combined with capecitabine in the treatment of treated patients with HER2-negative breast cancer
Time of Update: 2022-01-08
Therefore, scholars from Australia carried out a phase II clinical study AGMT MBC-6 to evaluate the efficacy of bendamustine combined with capecitabine in the treatment of previously treated MBC patients .
-
Metz inventory: ten major advances in lung cancer in 2021
Time of Update: 2022-01-08
The exploration of tumor vaccines, the initial resultsAtalante-1 study: A randomized phase III clinical study to evaluate OSE2101 [Tedopi, an anti-cancer vaccine (modified epitopes are limited to HLA-A2+ from 5 tumor-associated antigens)] compared to standard treatment (Docetal) The effectiveness and safety of NSCLC patients after immune checkpoint inhibitor therapy failed .
-
ASH 2021: The second-line Axicabtagene Cilouleucel treats relapsed/refractory DLBCL with better efficacy
Time of Update: 2022-01-08
Lymphoma diagnosisIn the preliminary analysis of the ZUMA-7 trial, axicabtagene ciloleucel (axi-cel) showed an advantage over standard treatment in patients with relapsed/refractory large B-cell lymphoma (DLBCL), and the median event-free survival rate increased by 4 The 2-year event-free survival rate is increased by 2.
-
HPV vaccination has been universally launched in many places in China. Are we not far from "vaccine freedom"?
Time of Update: 2022-01-08
In December 2020 , the National Office of Patriotic Health and Health and the Office of the Healthy China Action Promotion Committee issued the "Notice on Carrying out the Pilot Work of Healthy City Construction to Promote the Innovative Model of Healthy China Action", which officially included the prevention and treatment of cervical cancer as the action goal .
-
Cell: There are three states of cancer cells!
Time of Update: 2022-01-08
Does RNA expression pattern affect drug response, and whether it can be used to identify tumor-sensitive treatment methods Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer" .
-
Thyroid: The relationship between body mass index and thyroid cancer risk
Time of Update: 2022-01-08
Although previous meta-analysis showed a dose-response relationship between body mass index (BMI) and thyroid cancer risk, the evidence in Asian populations is very limited .
-
European Radiology: Reproducible imaging prediction of glioma molecular subtypes and risk stratification through a structured reporting system
Time of Update: 2022-01-08
Use a structured reporting system to diagnose and describe MRI features, including contrast enhancement patterns, necrosis, margins, edema, T2/FLAIR mismatch, internal cysts, and higher cerebral blood volume than normal cortex .
-
European Radiology: Dual-energy CT to distinguish benign and malignant nasal cavity lesions
Time of Update: 2022-01-08
Blood vesselRecently, published in the E uropean a journal Radiology study by comparing simulation SECT, conventional MRI and DWI, explore the DECT value in distinguishing benign and malignant lesions of the sinuses , provide a reference for the accurate diagnosis of sinus disease .
-
J Urol: Does androgen blocking therapy cause dementia?
Time of Update: 2022-01-08
A national longitudinal registry of prostate cancer patients assessed the relationship between cumulative ADT exposure and the onset of dementia.
A national longitudinal registry of prostate cancer patients assessed the relationship between cumulative ADT exposure and the onset of dementia.
-
Kang Ning Jereh HER2 double anti-KN026 combined with chemotherapy for the treatment of gastric cancer clinically approved press release
Time of Update: 2022-01-08
KN026-CSP-001 is a randomized, multicenter, phase II/III clinical study to evaluate the effectiveness and safety of KN026 combined with chemotherapy in patients with HER2-positive gastric cancer (including gastric-esophageal junction adenocarcinoma) who have failed first-line treatment , Professor Xu Jianming from the General Hospital of the Chinese People’s Liberation Army served as the principal investigator .
-
Explore the headlines The Lancet: As soon as the five types of cancer are discovered, early screening and early diagnosis are not empty words!
Time of Update: 2022-01-08
8% (22009/41671) of the patients are already in the advanced stage as soon as they are diagnosed ( Phase III-IV) research suggests that China urgently needs to raise awareness of cancer prevention and implement early cancer screening .
-
Ther Adv Med Oncol: Reveal the 20-year treatment and clinical prognosis of patients with HER2+ advanced breast cancer (PANHER study)
Time of Update: 2022-01-08
For patients who have not previously been treated with patolizumab, the median PFS of second-line lapatinib/capecitabine or TDM-1 treatment was 8 months (95% CI, 6.
For patients who have not previously been treated with patolizumab, the median PFS of second-line lapatinib/capecitabine or TDM-1 treatment was 8 months (95% CI, 6.
-
Clin Cancer Res: Treatment of non-Hodgkin's lymphoma with anti-CD79B antibody drug conjugate DCDS0780A
Time of Update: 2022-01-07
The anti-CD79B antibody drug conjugate DCDS0780A can induce deep remission in patients with B-cell non-Hodgkin's lymphoma .
The anti-CD79B antibody drug conjugate DCDS0780A can induce deep remission in patients with B-cell non-Hodgkin's lymphoma .
Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study.
-
Nature: Ketogenic diet cannot fight cancer, but calorie restriction can cut off lipid supply and inhibit tumor growth
Time of Update: 2022-01-07
What are the effects of these dietary adjustments on cancer?On October 20, 2021, Matthew Vander Heiden of the Massachusetts Institute of Technology and others published a research paper titled: Low glycaemic diets alter lipid metabolism to influence tumour growth in Nature .
-
In 2021, more than 30 new drugs will be listed on the priority review, and oncology drugs are still the main line of domestic innovation
Time of Update: 2022-01-07
It is understood that the priority review and approval procedure is applicable to urgently needed clinically needed drugs, new drugs for the prevention and treatment of major infectious diseases and rare diseases; new varieties, dosage forms and specifications of medicines for children; and urgently needed vaccines and innovative vaccines .
-
Is statin "out of the circle" again?
Time of Update: 2021-12-31
Recently, JAMA Oncology, one of the top tumor journals, published a study on the topic "Outcomes of Screening for Prostate Cancer Among Men Who Use Statins", "Medical Oncology Channel" Professor Zhu Yao from the Cancer Hospital of Fudan University was specially invited to share this research and interpret the research results from a clinical and practical perspective, which is a "down-to-earth" clinical dry goods for the majority of doctors and patients online .
-
Professor Zhang Liling: New progress and practice sharing of targeted therapy for peripheral T-cell lymphoma
Time of Update: 2021-12-30
The multi-center, single-arm phase II study of the dual SYK/JAK inhibitor Cerdulatinib monotherapy for relapsed and refractory PTCL showed that the overall response rate of ALCL and PTCL patients with the follicular helper T-cell lymphoma phenotype was higher than that of other subtypes.
-
Cell Metabolism directly regulates glycolysis lncRNA—NEAT1
Time of Update: 2021-12-30
. In summary, the research team revealed that lncRNA NEAT1 is a new regulator of glycolysis pathway, and the high expression of NEAT1 promotes the occurrence, proliferation and metastasis of breast cancer .
-
Deqi Pharmaceutical's first product, Civio®, was approved for the market, and the new mechanism of action has broad application prospects｜Press release
Time of Update: 2021-12-30
HK) announced today that the National Medical Products Administration (NMPA) has approved The new drug application (NDA) of Civio® (Celinisol, ATG-010), through the combination with dexamethasone, the treatment of previous treatment and at least one proteasome inhibitor, an immunomodulator And an anti-CD38 monoclonal antibody refractory relapsed or refractory multiple myeloma (rrMM) .
